Rheumatology International

, Volume 29, Issue 9, pp 1113–1115

Treatment of intractable pulmonary hemorrhage in two patients with childhood systemic lupus erythematosus

Letter to the Editor

DOI: 10.1007/s00296-009-0886-7

Cite this article as:
Moradinejad, M.H. Rheumatol Int (2009) 29: 1113. doi:10.1007/s00296-009-0886-7


Systemic lupus erythematosus (SLE) is a chronic autoimmune disease of unknown etiology with multisystem involvement. A number of pulmonary complications including pleuritis, pneumonitis, infectious pneumonia, and pulmonary hemorrhage, have been reported in patients with SLE. Pulmonary hemorrhage is a major life-threatening manifestation in children and adolescents with SLE. Mycophenolate mofetil is an immunosuppressive agent used in solid organ transplantation, and it may play an increasing role in autoimmune disease. In this report, we present two cases of childhood SLE with recurrent pulmonary hemorrhage, which were unresponsive to treatment with high-dose corticosteroids, cytotoxic therapy, IVIG, plasmaphoresis, and supportive therapy, but responded to IV mycophenolate mofetil. A multimodal therapy including mycophenolate mofetil was effective in treatment of these two children.


Systemic lupus erythematosusLupus pneumonitisPulmonary hemorrhageMycophenolate mofetil

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Children’s Hospital Medical CenterTehran University of Medical SciencesTehranIran